Algernon Pharmaceuticals Inc. C.AGN

The Spirit Molecule (DMT)

[C10H12N2]

If BIG PHARMA does pay Algernon attention it will be with CA$H.
My guess is the entire scientific community will tune into the DMT clinical trial and definitely @ Phase 2 if not Phase 1.
Keeping in mind it's the World's 1st such clinical trial with DMT.
It's an interesting story that might even get a mention by crazy Joe Rogan.
All the other psych biotechs out there are drilling down on mental health disorders/feeling better.
Algernon is drilling down on the damage from Acute Stroke/healing better.
Stroke ain't no joke.
The market will take Algernon seriously with or without the listing to Nasdaq.
However, Nasdaq will place Algernon among the cream of the crop of biotech stocks.
2022 can't unfold soon enough.
Bring on the DMT Phase 1 clinical trial.

[nodaytrader]

And there is a possibility that some pharma company has already made an approach. If they came in with a "stinkbid" that Moreau turned down, he would be smart not to make that public. Why humiliate an interested buyer? I am not saying it's likely - only that it's possible.

[C10H12N2]

Agreed. It's hard to believe there's nobody out there with deep pockets not wanting a piece of Algernon's novel approach to Stroke treatment. We should know rather quickly after Phase 1 if we can shake the money tree for some form of non dilutive financing - Partnership/Grant/$omething.

[nodaytrader]

True, but I still think that Ifenprodil has to be of interest to some. Early test results indicated that it was more effective than current treatments for chronic cough including, as I recall, Merck.

[C10H12N2]

I'm not dismissing the Ifenprodil program, but it has been beaten like a dead horse. The Chronic Cough angle remains an anchor around our necks. The timelines for anything mentioned about Chronic Cough continue to change even as of late with full enrollment not happening in December. News release after news release and the dates never line up. Eventually they will because the law of averages

[nodaytrader]

As I understand it, Algernon was never intended to be a production company but one that will sell or license use of repurposed drugs. So It is setting out its stall and on that stall are; Ifenprodil for chronic cough Ifenprodil for IPF Ifenprodil for Pancreatic Cancer Ifenprodil for Small Cell Lung Cancet (Orphan Drug) DMT as part of stroke rehabilitation therapy DMT as possible treatment for

[C10H12N2]

IMO, your list is upside down. The timeline and trend is now with DMT. We overshot the runway by more than a year with IPF and Chronic Cough is off the schedule for a standalone Phase 2 clinical trial. We will be at Phase 2 of DNT and well on the way before IPF comes back around for yet another Phase 2 clinical trial. Your timeline would push everything into 2024 or 2025 before we see some serious

[nodaytrader]

Perhaps I didn't explain myself very well. I am not advocating for Ifenprodil or suggesting that the company do anything different from what they are now doing. A stallholder knows that most of his product will attract little interest - but as long as there's a chance that somebody might be interested, he will lay it out. There may be other products that are much more profitable but his

[C10H12N2]

I agree the goal is to have multiple shots at goal. However, what I'm saying as an investor is we should not overshoot the runway with stacked up clinical trials that we thus far would need to dilute like drunken monkey's to facilitate in a proper way. GH Research has but two avenues with it's DMT program. You don't need umpteen avenues at the same time to realize a billion dollar

[C10H12N2]

Follow up: Hopefully this "Peers" chart will stick this time. If not, just click on the "Peers" link above. it's all there.

[nodaytrader]

Thank you. That chart raises the question of why is it that Algernon's market cap is low compared to its peers. today's trading shows the price as coming down and a company called Integral Wealth Securities Seems to have led the way and is quite active in the lower bidders list as they present themselves as providing investment advice to clients, I am puzzled at how this activity helps